NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Jonathan E. Dowell et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018David S. Ettinger, Miranda Hughes, Dara L. Aisner et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 471
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerLecia V. Sequist, Joan H. Schiller, Joachim von Pawel et al.|Journal of Clinical Oncology|2011Cited by 379
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81